Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1517 • 2019 ACR/ARP Annual Meeting
Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis
Iain McInnes¹, Dafna Gladman ², Atul Deodhar ³, Corinne Miceli-Richard ⁴, Peter Nash ⁵, Naveed Sattar ⁶, Nehal Mehta ⁷, Darren Asquith ⁸, Jianyuan Wang ⁹, Hanno Richards ⁹, Luminita Pricop ¹⁰ and Abhijit Shete ⁹, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Oregon Health & Science University, Portland, OR, ⁴Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ⁵University of Queensland, Brisbane, Queensland, Australia, ⁶Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁸Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment…
Abstract Number: 1777 • 2019 ACR/ARP Annual Meeting
The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis
Daniele Mauro¹, Federica Macaluso ², Alessandra Nerviani ³, Marie-Astrid Boutet ³, Aroldo Rizzo ⁴, Riccardo Alessandro ², Giuliana Guggino ², Costantino Pitzalis ³ and Francesco Ciccia ⁵, ¹Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, England, United Kingdom, ²University of Palermo, Italy, Palermo, Italy, ³Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁴Pathology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy., Palermo, Italy, ⁵University of Campania L. Vanvitelli, Naples, Italy
Background/Purpose: Interleukin 12 (IL-12) and 23 (IL-23) may play a pivotal role in the pathogenesis of inflammatory diseases, including Spondyloarthritis (SpA). In mice, the deubiquitinase…
Abstract Number: 2448 • 2019 ACR/ARP Annual Meeting
Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission
Marie Moly¹, Cédric Lukas ², Jacques Morel ¹, Bernard Combe ³ and Gaël Mouterde ⁴, ¹CHU Montpellier, Montpellier, France, ²Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴CHU Montpellier and Univ Montpellier, Montpellier, France
Background/Purpose: Assessment of disease activity in psoriatic arthritis (PsA) requires evaluation of multiple aspects and can be difficult. Perception of disease activity by patient and…
Abstract Number: 2468 • 2019 ACR/ARP Annual Meeting
JAK-STAT Signaling System in Pannus Formation of Psoriatic Arthritis: A Therapeutic Target
Siba Raychaudhuri¹ and Smritikana Raychaudhuri ², ¹UC Davis School of Medicine, Sacramento, CA, ²UC Davis School of Medicine, Davis, CA
Background/Purpose: Psoriatic arthritis (PsA) involves inflammation of the joint synovium where synovial cells (FLS) are the target for T cell activated cytokines for pannus formation.…
Abstract Number: 2489 • 2019 ACR/ARP Annual Meeting
Differences in Clinical Characteristics, Quality of Life, Disability, and Work Productivity in Psoriatic Arthritis Patients by Gender: Findings from a Cross-sectional Survey in the US and Europe
Laure Gossec¹, Jessica Walsh ², Kaleb Michaud ³, Steve Peterson ⁴, Elizabeth Holdsworth ⁵, Chetan Karyekar ⁴, Nicola Booth ⁶, Jessalyn Kemp ⁷, Soumya Chakravarty ⁸, Shelly Kafka ⁹ and Alexis Ogdie ¹⁰, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Nebraska Medical Center, Omaha, NE, ⁴Janssen Global Services, LLC, Horsham, PA, ⁵Adelphi Real World, Manchester, England, United Kingdom, ⁶Adelphi Real World, Bollington, United Kingdom, ⁷Adelphi Real World, Manchester, United Kingdom, ⁸Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, ⁹Janssen Scientific Affairs, LLC, Horsham, PA, ¹⁰Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) prevalence is equal in men and women, though gender may play a role in driving mechanisms of PsA leading to differences…
Abstract Number: 2512 • 2019 ACR/ARP Annual Meeting
A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis
Julie Taylor ¹, Laura Coates² and Emma Dures ¹, ¹Department of Nursing and Midwifery, University of the West of England, Bristol and Academic Rheumatology, University Hospitals NHS Trust, Bristol, England, United Kingdom, ²University of Oxford, Oxford, United Kingdom
Background/Purpose: European League Against Rheumatism Treatment recommendations support implementing a treat-to-target (T2T) approach in psoriatic arthritis (PsA) based on the findings of the TICOPA trial.…
Abstract Number: 421 • 2019 ACR/ARP Annual Meeting
An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Vibeke Strand¹, Philip Mease ², Ervant Maksabedian ³, Bradley Stolshek ³, Lyrica Liu ³, David Collier ³, Gregory Kricorian ³ and Joseph Merola ⁴, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Amgen Inc., Thousand Oaks, CA, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Health-related quality of life is impacted in patients (pts) with psoriatic arthritis (PsA). Patient-reported outcomes (PROs) are an important means of measuring treatment improvements…
Abstract Number: 1011 • 2019 ACR/ARP Annual Meeting
Single Cell RNA Sequencing of Patients with Psoriatic Disease
Rohan Machhar¹, Kun Liang ², Remy Pollock ¹ and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Krembil Research Institute, U of Toronto, Toronto, ON, Canada
Background/Purpose: Delayed diagnosis of psoriatic arthritis (PsA) can lead to poor clinical outcomes. A large proportion of PsA patients remain undiagnosed due to a lack…
Abstract Number: 1431 • 2019 ACR/ARP Annual Meeting
Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study
René-Marc Flipo¹, Florence Tubach ², Jean Ouaniche ³, Philippe Goupille ⁴, Eric Lespessailles ⁵, Najat Gouyette ⁶, Naoual Harid ⁷, Saannya Sequiera ⁸, Philippe Bertin ⁹ and Bruno Fautrel ¹⁰, ¹Roger Salengro University-Hospital, Lille , France, Lille, France, ²Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, ³Private Practice , Toulon, France, Toulon, France, ⁴Tours University-Hospital, Tours, France, Tours, France, ⁵Orléans Regional Hospitals, Orléans ,France, Orléans, France, ⁶MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, ⁷MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, ⁸ClinSearch ,Malakoff, France, Malakoff, Ile-de-France, France, ⁹Limoges University-Hospital , Limoges, France, Limoges, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: The GO PRACTICE study was initiated following a demand by the French Health Authorities for long-term data on the real-life use of golimumab (GLM)…
Abstract Number: 1518 • 2019 ACR/ARP Annual Meeting
Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases
Matthew Thomas ¹, Gavin Shaddick ², Rachel Charlton ¹, Charlotte Cavill ³, Richard Holland ⁴, Florenzo Iannone ⁵, Giovanni Lapadula ⁶, Simona Lapriore ⁵, Jakub Závada ⁷, Michal Uher ⁸, Karel Pavelka ⁹, Lenka Szczukova ¹⁰, Prodromos Sidiropolous ¹¹, Irini Flouri ¹¹, Burkhard Moeller ¹², Michael J. Nissen ¹³, Ruediger B. Mueller ¹⁴, Almut Scherer ¹⁵, Neil McHugh¹ and Alison Nightingale ¹, ¹University of Bath, Bath, United Kingdom, ²University of Exeter, Exeter, United Kingdom, ³Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵University of Bari, Bari, Italy, ⁶Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy., Bari, Italy, ⁷Institute of Rheumatology, Prague, Prague, Czech Republic, ⁸Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic, ⁹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ¹⁰Masaryk University, Brno, Czech Republic, ¹¹University of Crete, Crete, Greece, ¹²University Hospital Bern, Bern, Switzerland, ¹³University Hospital Geneva, Geneva, Switzerland, ¹⁴Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ¹⁵SCQM Foundation, Zürich, Switzerland
Background/Purpose: A large proportion of psoriatic arthritis (PsA) patients are prescribed a tumour necrosis factor inhibitor (TNFi) in combination with methotrexate (MTX), however the value…
Abstract Number: 1821 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain
Ana-Maria Orbai ¹, Rocco Ballerini ², Richard C. Chou ³, Stephen Rozzo ², Alan Mendelsohn² and Luis R. Espinoza ⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ³University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁴Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo (PBO)-controlled, phase 2b study (NCT02980692)…
Abstract Number: 2449 • 2019 ACR/ARP Annual Meeting
Assessing Risk of PsA Progression: Results from a Combined Psoriasis-PsA Center Cohort
Rebecca Haberman¹, Samrachana Adhikari ¹, Deborah Ramirez ², Eileen Lydon ¹, Malavika Attur ¹, Bruno Lovisi ², Soumya Reddy ¹, Andrea Neimann ¹, Andrea Troxel ¹ and Jose Scher ³, ¹NYU School of Medicine, New York City, ²NYU School of Medicine, New York, ³New York University School of Medicine, New York, NY
Background/Purpose: About 30% of patients with skin psoriasis (PsO) develop psoriatic arthritis (PsA). The reasons for why only some progress to synovio-enthesial disease from skin…
Abstract Number: 2470 • 2019 ACR/ARP Annual Meeting
Relationship Between Serum Calprotectin Level and Presence of Subclinical Atherosclerosis and Arterial Stiffness in Patient with Psoriatic Arthritis
Isaac T. Cheng¹, Martin M Li ¹, Edmund K Li ¹, Alex P Lee ¹ and Lai-Shan Tam ¹, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Calprotectin is a member of S100 leukocyte. Serum calprotectin is a sensitive biomarker of disease activity in patients with psoriatic arthritis (PsA). While various…
Abstract Number: 2490 • 2019 ACR/ARP Annual Meeting
The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype
Meital Yerushalmi¹, Osvaldo Espin-Garcia ², Justine (Yang) Ye ³, Remy Pollock ⁴, Sara Rahmati ³, Lihi Eder ⁵, Mark Silverberg ⁶ and Vinod Chandran ⁷, ¹University of Toronto, University Health Network, Toronto, ON, Canada, ²Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Krembil Research Institute, University Health Network, Toronto, Canada, ⁵Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Psoriasis is an inflammatory skin disease. Psoriatic arthritis (PsA) is an inflammatory arthritis that affects 30% of psoriasis patients. The heterogeneity of psoriatic disease…
Abstract Number: 2513 • 2019 ACR/ARP Annual Meeting
Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Laura Coates¹, Andrew Bushmakin ², Oliver FitzGerald ³, Dafna Gladman ⁴, Lara Fallon ⁵, Joseph Cappelleri ², Ming-Ann Hsu ⁶ and Philip Helliwell ⁷, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³University College Dublin, Dublin, Ireland, ⁴University of Toronto, Toronto, ON, Canada, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a complex heterogeneous disease associated with multiple domains. Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite disease activity measure…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].